NASDAQ: ETONEton Pharmaceuticals Inc Stock
$45.83+0.69 (+1.53%)
Updated Aug 4, 2026
ETON Price
$45.83
Fair Value Price
$2.88
Market Cap
$1.26B
52 Week Low
$14.27
52 Week High
$50.18
P/E
-916.6x
P/B
41.01x
P/S
7.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$86.93M
Earnings
-$1.48M
Gross Margin
54.8%
Operating Margin
2.35%
Profit Margin
-1.7%
Debt to Equity
2.19
Operating Cash Flow
$16M
Beta
0.76
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ETON Overview
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ETON's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +28.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
C
ETON
Ranked#5 of 55
Ranked#5 of 55
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.44 | A | |
| $36.50 | A | |
| $27.62 | A |
Be the first to know about important ETON news, forecast changes, insider trades & much more!
ETON News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ETON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ETON ($45.83) is overvalued by 1,490.35% relative to our estimate of its Fair Value price of $2.88 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ETON ($45.83) is not significantly undervalued (1,490.35%) relative to our estimate of its Fair Value price of $2.88 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ETON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ETON due diligence checks available for Premium users.
Valuation
ETON fair value
Fair Value of ETON stock based on Discounted Cash Flow (DCF)
Price
$45.83
Fair Value
$2.88
Overvalued by
1,490.35%
ETON ($45.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ETON ($45.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ETON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ETON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-916.6x
Industry
-2.85x
Market
14.64x
ETON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
41.01x
Industry
1.57x
ETON is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ETON's financial health
Profit margin
Revenue
$24.3M
Net Income
$1.6M
Profit Margin
6.4%
ETON's Earnings (EBIT) of $2.04M... subscribe to Premium to read more.
Interest Coverage Financials
ETON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$97.7M
Liabilities
$67.1M
Debt to equity
2.19
ETON's short-term assets ($53.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ETON's short-term assets ($53.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ETON's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ETON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.4M
Investing
-$15.1M
Financing
$1.4M
ETON's operating cash flow ($15.84M)... subscribe to Premium to read more.
Debt Coverage Financials
ETON vs Pharmaceutical Stocks
Eton Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.